Rhabdomyosarcoma is a muscle-derived malignant tumor mainly affecting children. The most frequent variant, embryonal rhabdomyosarcoma (ERMS) is characterized by overexpression of the transcription factor, PAX7 which prevents ERMS cells from exiting the cell cycle and terminally differentiating. However, a role for PAX7 in the invasive properties of ERMS cells has not been investigated in detail thus far. Here we show that ectopic expression of receptor for advanced glycation end-products (RAGE) in human ERMS cells results in the activation of a RAGE/myogenin axis which downregulates PAX7 by transcriptional and posttranslational mechanisms, as in normal myoblasts, and reduces metastasis formation. High PAX7 sustains migration and invasiveness in ERMS cells by upregulating EPHA3 and EFNA1 and downregulating NCAM1 thus decreasing the neural cell adhesion molecule (NCAM)/polysialylated-NCAM ratio. Microarray gene expression analysis shows that compared with the RAGE -ve TE671/ WT cells and similarly to primary human myoblasts, TE671/ RAGE cells show upregulation of genes involved in muscle differentiation and cell adhesion, and downregulation of cell migration related and major histocompatibility complex class I genes. Our data reveal a link between PAX7 and metastasis occurrence in ERMSs, and support a role for the RAGE/myogenin axis in metastasis suppression. Thus, low RAGE expression in ERMS primary tumors may be predictive of metastatic behavior.
Introduction
Rhabdomyosarcoma (RMS) is a highly malignant tumor of skeletal muscle origin accounting for more than 50% of soft tissue sarcomas in childhood (1, 2) . RMS cells resemble muscle precursor cells that fail to exit the cell cycle and undergo terminal differentiation (3) . Indeed, the expression of markers of the myogenic cell lineage (i.e. myogenin, desmin, MyoD and PAX7) is a hallmark of RMSs. Alveolar RMSs (ARMSs) and embryonal RMSs (ERMSs) are the most frequent variants, with ERMSs accounting for 60-70% of RMSs. Most ARMSs are associated with t(2,13)(q35;q14) or t(1,13)(p36;q14) chromosomal translocation, leading to the expression of the chimeric transcription factors, PAX3/FOXO1A and PAX7/FOXO1A, respectively (2) . In contrast, ERMSs lack recurrent chromosomal translocations, are frequently characterized by loss of heterozygosity (LOH) and imprinting (LOI) on different chromosomal loci, and typically overexpress PAX7 (2, 4) . Whereas ARMSs are believed to originate mainly from uncommitted mesenchimal cells, ERMSs are suggested to originate from muscle precursor cells [i.e. activated satellite cells and their downstream progeny, the myoblasts] (4, 5) .
Receptor for advanced glycation end-products (RAGE), encoded by AGER, is a multiligand receptor of the immunoglobulin superfamily involved in physiological and pathological processes, such as neuronal survival and differentiation, myogenesis, neurodegeneration, Alzheimer's disease, inflammation, atherosclerosis, tumor growth and metastasis (6, 7) . We reported that RAGE (i) is expressed in muscle tissue during embryonic development (8) ; (ii) is not expressed in adult myofibers but becomes expressed in activated satellite cells and proliferating/differentiating myoblasts during muscle regeneration (9) ; and (iii) stimulates the promyogenic kinase, p38 mitogen-activated protein kinase (MAPK), and myogenin expression in myoblasts, thereby reducing cell proliferation and enhancing differentiation (8, 10) . Moreover, functional inactivation of RAGE in myoblasts resulted in the acquisition of a malignant phenotype characterized by decreased apoptosis and increased proliferation, migration and invasiveness in vitro, and tumor formation in vivo (10) . Conversely, ectopic expression of RAGE in the human ERMS-derived cell line, TE671, which does not express RAGE, resulted in the activation of a Rac-Cdc42-MKK6-p38 MAPK pathway leading to reduced proliferation and invasiveness and a partial rescue of myogenic potential (11) . Information is lacking about the role of RAGE in ERMS invasiveness in vivo and occurrence of metastasis.
The tumor properties of ARMSs and ERMSs have been associated to PAX genes because of the transcriptional hyperactivity of PAX3/ FOXO1A or PAX7/FOXO1A fusion transcripts in ARMSs, and the high level of PAX7 in ERMSs. Indeed, PAX activity has been shown to regulate the expression of cell surface molecules involved in cell adhesion, migration and invasiveness, particularly Met (hepatocyte growth factor receptor), ephrins (EFNs) and Eph receptors (EPHs) and neural cell adhesion molecule (NCAM) in various cell types (12) . However, specific effects of PAX7 on the expression of these molecules in ERMS cells have not been reported thus far. RAGE activity in myoblasts results in repression of PAX7 expression through upregulation of myogenin and myogenin binding to consensus sequences in the Pax7 promoter (9) . Additionally, myogenin reduces PAX7 levels by a proteasome-mediated mechanism (13) . We recently found that ERMS cell lines express no or low RAGE which results in high PAX7 levels that in turn cause reduction of RAGE, MyoD and myogenin levels ultimately leading to unrestricted proliferation and absence of myogenic differentiation (14) . In this study, we analyzed the possibility that loss of RAGE expression/activity in muscle precursor cells and ERMS cells and the consequent upregulation of PAX7 expression might contribute to the acquisition of a metastatic behavior.
We show that in ERMS cells and normal myoblasts high levels of PAX7 upregulate EPHA3 and EFNA1, and downregulate the expression of NCAM1, thus causing a proportional increase in polysialylated NCAM, ultimately leading to enhanced migration and invasiveness. Ectopic expression of RAGE in ERMS cells restores a RAGE-myogenin axis that downregulates PAX7 expression transcriptionally and post-translationally, as in normal myoblasts, and dramatically reduces tumorigenesis and metastasis formation. Moreover, compared with wild-type TE671 (TE671/WT) cells, TE671 cells stably transfected with AGER (TE671/RAGE cells) show increased expression of genes involved in myogenic differentiation and cell adhesion, reduced expression of genes involved in cell migration and a dramatic downregulation of major histocompatibility complex (MHC) class I genes that might promote 'missing self' recognition and killing by natural killer (NK) cells in vivo (15) .
PAX7 sustains ERMS invasiveness

Materials and methods
Animal treatments
Six-week-old athymic nu/nu female mice (Harlan Laboratories) previously irradiated with 400 rad whole-body (16) were injected with 1.2 × 10 6 TE671/WT or TE671/RAGE cells into the peritoneal cavity. Mice were maintained in a sterile environment and received food and water ad libitum. No drugs were added to drinking water. After six weeks mice were killed to evaluate tumorigenesis and metastasis formation. In other experiments, 5 × 10 6 WT or primary Ager -/-myoblasts were injected into the peritoneal cavity of athymic mice and tumorigenesis was evaluated up to 3 months. Injury of Tibialis anterior muscles of Ager -/-mice was performed by single or double (the second one 3 weeks after the first one) intramuscular injection with BaCl 2 (9) . Mice were monitored for RMS formation up to 7 weeks after last injury. Approval of use of animals was obtained by the Ethics Committee of the Perugia University and the Ministry of Health, Italy.
Cell culture TE671 (ATCC #CRL-8805), RD (ATCC #CCL-136) and TE671/RAGE cells obtained by stable transfection of TE671 cells with full-length human RAGE (11) were cultured in growth medium (GM) or differentiation medium (DM) as decribed (14) . After receipt, TE671 and RD cells were expanded and aliquots were frozen in liquid nitrogen; each aliquot was used for no more than 10 passages. Primary human myoblasts (hu-Ms) were purified from Vastus lateralis muscle biopsies of young healthy untrained men, characterized and grown as described (17) . Subjects underwent voluntary biopsy within a protocol approved by the Ethics Committee for Biomedical Research, University of Chieti-Pescara, Chieti, Italy (Prot. 1884 COET). Primary myoblasts from WT (C57BL/6) (Harlan Laboratories) and Ager -/-mice were isolated, characterized and cultivated as described (9) . Cells were maintained in a humidified atmosphere containing 5% CO 2 at 37°C. Where indicated, cells were treated for 6 h with MG132 (25 μM, Sigma-Aldrich) or vehicle (dimethyl sulfoxide) prior to further processing.
Histology, immunohistochemistry and immunofluorescence
See Supplementary material, available at Carcinogenesis Online for details.
Overexpression and gene knockdown
Overexpression of AGER, murine Myog or PAX7 were obtained by transiently transfecting the cells with 9 μg of pcDNA3/RAGE, pEMSV-myogenin (13) or pcDNA3/PAX7 (18) expression vectors, respectively, using jetPEI (Polyplus Transfection) as recommended by the manufacturer. Control cells were transfected with empty vectors. Transfection efficiency was ~35%. PAX7 knockdown in ERMS cells and Ager -/-myoblasts was carried out by transfecting the cells with PAX7 Small interfering RNA (siRNA)(h) or Pax7 siRNA(m) (both of which consisted of a pool of three target-specific siRNAs; Santa Cruz Biotechnology), respectively using INTERFERin (Polyplus Transfection) according to the manufacturer's instructions. Control cells were transfected with the nontargeting, siRNA-A (Santa Cruz Biotechnology). Transfection efficiency was ~40%. Cells were cultured in GM for 48 h and treated as specified in figure legends prior to processing by PCR or western blotting.
PCR, real-time PCR and western blotting
Migration and invasiveness assays
Migration and invasiveness assays were performed as described (11) . See Supplementary material for details, available at Carcinogenesis Online.
Microarray analysis
Total RNA from hu-Ms, TE671/WT and TE671/RAGE cells cultured in GM was purified using RNeasy Plus Mini kit (QIAGEN) according to manufacturer's instructions. In the case of hu-Ms equal amounts of total RNA from young healthy untrained men (n = 2; 25.0 ± 5.0 years old) were mixed together prior to microarray analysis. See Supplementary material, available at Carcinogenesis Online for further details.
Statistical analysis
Each experiment was performed at least three times. Representative experiments are shown unless stated otherwise. Counts were performed by three independent operators. The mean values ± SD are reported, unless specified otherwise. The data were subjected to analysis of variance with SNK post hoc analysis using a statistical software package (GraphPad Prism version 4.00, GraphPad).
Results
Ectopic expression of RAGE in TE671 cells results in reduced metastasis formation and growth
All TE671/WT cell-injected mice developed tumors and lung metastases mainly located within pulmonary vessels ( Figure 1A-C) .
Contrariwise, only 45% of TE671/RAGE cell-injected mice developed tumor masses with lung metastases occurring in 55% of mice that developed intraperitoneal tumor ( Figure 1A-C) . Noteworthy, lung metastases in mice injected with TE671/RAGE cells were strongly reduced in number (27.0 ± 12.2 and 1.04 ± 0.6 metastases/ section in mice injected with TE671/WT or TE671/RAGE cells, respectively) ( Figure 1D ), and consisted of very small (average size 4.65 ± 1.0 × 10 3 µm 2 ) groups of cells within minor pulmonary vessels compared with the larger (average size 3.35 ± 0.5 × 10 4 µm 2 ) groups found in TE671/WT cell-injected mice ( Figure 1B) . Moreover, we found liver-associated tumor masses, located at the edge of liver sections and beneath the fibrous capsule, in 95 and 25% mice injected with TE671/WT and TE671/RAGE cells, respectively, accounting for 95 and 55% of tumor-bearing mice, respectively (Supplementary Figure 1A and B, available at Carcinogenesis Online). Lung metastases and liver-associated tumors resulted positive for the RMS markers, PAX7 and myogenin (Supplementary Figure 1C and D, available at Carcinogenesis Online) confirming their derivation from the injected cells. Thus, ectopic expression of RAGE in RAGE −ve ERMS cells, besides reducing tumor formation, translates into reduced lung metastasis occurrence and growth and liver colonization once injected into the peritoneal cavity.
Low or absent RAGE/myogenin activity increases PAX7 levels in and the invasive properties of ERMS and muscle precursor cells
The tumor properties of ERMSs have been associated to PAX7 gene activity because of the high expression level of PAX7 in these tumors (2, 4) . RAGE activity in ERMS and muscle precursor cells results in the activation of p38 MAPK and induction of myogenin expression (8, 10, 11) , and myogenin reduces PAX7 expression by a transcriptional and post-translational mechanism in normal myoblasts (9, 13) . Thus, we reasoned that the reduction of tumor and metastasis formation in TE671/RAGE cell-injected mice ( Figure 1 ) might be linked to the reduced PAX7 levels generated by RAGE-induced myogenin. The ERMS cell lines, TE671 and RD express higher PAX7 amounts compared with primary human myoblasts (hu-Ms) ( Treatment of TE671/WT cells in GM with the proteasome inhibitor, MG132, resulted in enhanced levels of PAX7 and myogenin ( Figure 2F ), in accordance with the reported mutual, proteasomedependent regulation of PAX7 and myogenin levels in myoblasts (13) . Overexpression of myogenin in TE671/WT cells in GM resulted in a significant reduction of PAX7 mRNA and protein, which was prevented by MG132 treatment ( Figure 2F ). Thus, when expressed in relatively high amounts, RAGE-induced myogenin regulates PAX7 expression and stability in ERMS cells in a similar manner to normal myoblasts (9, 13) , suggesting that the high expression levels of PAX7 in ERMSs might be due to the inability of these cells to express relatively high myogenin levels.
Next, we analyzed the relationship between RAGE and PAX7 expression in primary myoblasts isolated from WT and Ager -/-mice. Primary Ager -/-myoblasts express remarkably lower and higher levels of myogenin and PAX7, respectively, compared with WT myoblasts (9) , and exhibit increased myogenin and reduced PAX7 levels following forced expression of RAGE (9) . We found that primary Ager -/-myoblasts show much higher rates of migration and invasiveness in vitro (267.7 and 239.4% migrated and invading cells, respectively, compared with WT myoblasts) ( Figure 2G ). Moreover, Ager -/-myoblasts transfected with either AGER or specific Pax7 siRNAs exhibited reduced migration and invasiveness, with AGER transfection being more effective than Pax7 silencing (33.4 versus 25.2% and 36.8 versus 29.2% reduction in migrated and invading cells, respectively, compared with WT myoblasts) ( Figure 2G ). Accordingly, WT myoblasts transfected with PAX7 showed increased (41.6 and 28.7%, respectively) migration and invasiveness in vitro ( Figure 2G ) and a ~50% higher migration rate in 24 h wound-healing assays ( Figure 2H ). Together, these results suggest that absent or low RAGE signaling in ERMS cells and the consequent inability of these cells to express myogenin, determine accumulation of PAX7 which supports ERMS cell invasive properties.
PAX7 supports migration and invasiveness in ERMS cells by in ducing EPHA3 and EFNA1 and repressing NCAM1, thus leading to the accumulation of PSA-NCAM
PAX activity has been associated to the expression of cell surface molecules such as Met, EFNs and EPHs, and NCAM/polysialylated NCAM (PSA-NCAM) involved in cell adhesion, migration and metastasis (12) . Met is highly expressed in RMS cell lines (19) and is overexpressed and/or mutated in a variety of cancers wherein it promotes invasion and metastasis (20) ; altered expression of EFNs and/or EPHs is found in several tumor types and demonstrated to be involved in the occurrence of metastasis (21); and, NCAM polysialylation modulates the adhesive functions of NCAM and is suggested to be relevant for enhanced invasive and metastatic potential of tumor cells (22) . Thus, we examined the expression levels of these molecules in TE671/WT and TE671/RAGE cells. We found no significant differences in Met expression between TE671/WT and TE671/ RAGE cells at transcriptional (real-time PCR) and translational (Western blotting) levels (data not shown). However, by gene expression microarray analysis (see below) we found that compared with TE671/WT cells, TE671/RAGE cells showed downregulated (≤− Table 2 , available at Carcinogenesis Online). The most significantly affected genes, EPHA3 and EFNA1 resulted under the control of PAX7, since they were downregulated by PAX7-silencing in TE671/WT cells ( Figure 3A) , and upregulated after forced expression of PAX7 in TE671/RAGE cells ( Figure 3B ). Interestingly, co-silencing, but not single-silencing of EPHA3 and EFNA1 in TE671/WT cells ( Figure 3C ) translated into 21.5 and 16.6% reduced migration and invasiveness, respectively, as assayed by the use of cell culture inserts ( Figure 3D) , and a ~30% reduced migration rate in 8 h wound-healing assays compared with mocksilenced cells ( Figure 3E ). Additionally, compared with TE671/WT cells, TE671/RAGE cells showed a marked increase in NCAM levels and similar amounts of PSA-NCAM ( Figure 4A and B, left panels), leading to ~35% lower PSA-NCAM/NCAM expression ratio ( Figure 4B, left panels) . Accordingly, compared with WT myoblasts Ager -/-myoblasts showed reduced expression of NCAM (mRNA and protein) and similar amounts of PSA-NCAM, thus resulting in a ~265% higher PSA-NCAM/NCAM expression ratio ( Figure 4A and B, right panels). Silencing PAX7 in TE671/WT cells resulted in reduced PSA-NCAM/NCAM expression ratio ( Figure 4C , left panels), the opposite being found by overexpressing PAX7 in WT myoblasts ( Figure 4C, right panels) . In all cases, the observed changes in PSA-NCAM/NCAM ratios appeared strictly dependent on changes in NCAM expression levels rather than on polysialylation activity, since we found similar amounts of ST8SIAII polysialyltransferase in our experimental conditions ( Figure 4B and C) . NCAM1 expression in turn appeared to be affected by PAX7 activity since it was increased by PAX7 silencing in TE671/WT cells ( Figure 4D) , and decreased by PAX7 overexpression in WT myoblasts and TE671/RAGE cells ( Figure 4E ). Accordingly, tumor masses originated from injected TE671/RAGE cells were characterized by lower EphA3 and EFNA1 expression levels and higher NCAM levels compared with tumor masses originated from TE671/WT cells (Supplementary Figure 3A and C-E, available at Carcinogenesis Online). Moreover, lung metastases showed an increased expression of EphA3 and EFNA1, and a reduced expression of NCAM compared with their i.p. primary tumors (Supplementary Figure 3C -E, available at Carcinogenesis Online). Incidentally, lung metastases from TE671/RAGE cell tumors showed a weak or no RAGE expression (Supplementary Figure 3B , available at Carcinogenesis Online).
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1.2-fold change) EPHA3, A4, A5 and B2 and EFNA1, A3, A4 and B3 and upregulated (≥1.2-fold change) EPHA7 and EFNB2, with EPHA3 and EFNA1 showing the greatest (<−1.5-fold change) differential expression (Supplementary Table 2, available at Carcinogenesis Online). Interestingly, the expression of EPHA3 and B2 and EFNA1, A3, A4, B2 and B3 in hu-Ms was regulated in the same way as in TE671/ RAGE cells (Supplementary
Myogenin causes PAX7 downregulation which results in NCAM induction
Besides repressing PAX7 expression, transient transfection of TE671 and RD cells and WT myoblasts with a myogenin expression vector resulted in NCAM1 induction which translated into reduced and increased amounts of PAX7 and NCAM, respectively ( Figure 5A and B and Supplementary Figure 2E and F, available at Carcinogenesis Online). Immunofluorescence analyses confirmed that myoblasts transfected with PAX7 were characterized by undetectable levels of NCAM, whereas high fluorescence for NCAM was found in cells overexpressing myogenin ( Figure 5C ). Because myogenin reduces PAX7 levels and vice versa (14) , in order to assess whether myogenin or PAX7 is responsible for the observed changes in NCAM levels we knocked down either Myog, Pax7 or both in WT primary myoblasts in DM. We found that NCAM mRNA and protein levels correlated negatively with PAX7 and showed no correlation with myogenin levels in the experimental conditions tested ( Figure 5D and E), suggesting that a repressor activity of PAX7 rather than a stimulatory activity of myogenin is involved in the regulation of NCAM expression in muscle precursor cells.
Ectopic expression of RAGE in TE671 cells results in changes in gene expression profile that support a reduced metastatic behavior
We performed a comparative gene expression analysis in TE671/WT and TE671/RAGE cells. Hu-Ms were included in this analysis as the normal counterpart of ERMS cells. We used the advanced wholetranscript GeneChip Human Gene 1.0 ST Array System (Affimetrix) in which each gene is interrogated by multiple probes (median = 26) on different exons. Functional annotation clustering (DAVID 6.7 (23)) showed that, compared with TE671/WT cells, TE671/RAGE cells were characterized by upregulation of genes (n = 53) involved in muscle cell development and differentiation (Supplementary Table 3 , available at Carcinogenesis Online), as expected (11, 12) . About half of these genes were also upregulated in hu-Ms, whereas the other genes (including myosin light chain, myogenin, junctophilin 1, titin and troponin C) were downregulated or substantially unchanged in hu-Ms compared with TE671/WT cells (Supplementary Table 3 , available at Carcinogenesis Online). Next, we looked for a differential gene expression profile that might support the observed in vitro and in vivo reduced migration and invasiveness of TE671/RAGE cells. Compared with TE671/WT cells, TE671/RAGE cells showed upregulation of genes involved in cell adhesion (n = 36) and downregulation of genes involved in cell migration (n = 62) (Supplementary Table 4 , available at Carcinogenesis Online). Most of the upregulated and downregulated genes were also upregulated and downregulated (75 and ~60%, respectively) in hu-Ms compared with TE671/WT cells (Supplementary Table 4 , available at Carcinogenesis Online). Lastly, compared with TE671/WT cells, TE671/RAGE cells showed downregulation of MHC class I genes, which were upregulated or substantially unchanged in hu-Ms versus TE671/WT cells (Supplementary Table 5 , available at Carcinogenesis Online).
Deletion of Ager in muscle precursor cells is not sufficient per se for oncogenic conversion
We injected primary WT or Ager -/-myoblasts into the peritoneal cavity of athymic nude mice. No tumor or metastasis formation was found in either condition up to 3 months after injection (data not shown). Moreover, we induced a single or double injury in Tibialis anterior muscles of Ager -/-mice by intramuscular injection with BaCl 2 in order to elicit a massive SC activation and myoblast proliferation, and analyzed these animals for RMS formation up to 7 weeks after the last injury. No tumor formation was found either (data not shown). Moreover, Ager -/-mice did not develop RMSs spontaneously up to 2 years after birth (data not shown). Collectively, these results suggested that loss of RAGE expression in muscle precursor cells, while concurring to rhabdomyosarcomagenesis, is not sufficient for oncogenic conversion.
Discussion
RAGE has emerged as a promyogenic cell surface receptor playing a key role in promoting cell cycle exit and differentiation in muscle precursor and ERMS cells (8) (9) (10) (11) 14) . Here we show that ectopic expression of RAGE in TE671 ERMS cells translates into reduced ability to metastasize lungs following i.p. injection into immunocompromised mice (Figure 1B-D) . This appears to be linked to RAGE-induced PAX7 sustains ERMS invasiveness changes in the gene expression profile, which are at least in part dependent on downregulation of PAX7 levels consequent to the activation of a RAGE/myogenin axis.
RMSs are soft tissue sarcomas of muscle origin that typically express markers of myogenic differentiation despite their inability to exit the cell cycle and terminally differentiate. The ERMS variant is believed to originate from proliferating/differentiating muscle precursor cells and typically expresses high PAX7 levels which have been proposed to contribute to tumorigenesis in the absence of chromosomal translocations (4) . Indeed, PAX7 expression is inversely related to the expression of the terminal differentiation marker, myogenin, in fetal/adult myoblasts and ERMS tumors (18, 24, 25) , and upregulation of PAX7 in muscle precursor cells is causally linked to their high proliferation (14) and prevents their terminal differentiation (18, 26) .
It is known that RAGE engagement in myoblasts results in the activation of p38 MAPK and induction of myogenin (8, 9) ; myogenin, in turn, represses PAX7 expression by binding to consensus sequences in the PAX7 promoter and causes PAX7 degradation by a proteasomal-dependent mechanism (9, 13, 14) . Indeed, an inverse relationship exists between RAGE and myogenin protein levels and those of PAX7 in muscle precursor cells (9) . RAGE activity in RAGE-transfected ERMS cells also results in p38 MAPK-dependent induction of myogenin (11) , and, compared with TE671/WT cells, TE671/RAGE cells exhibited higher and lower amounts of myogenin and PAX7, respectively (14) . We show here that RAGE-induced myogenin reduces PAX7 levels in ERMS cells by a transcriptional and post-translational mechanism ( Figure 2F ), as in normal myoblasts (9,13), suggesting that due to absent or low RAGE, ERMS cells are unable to express levels of myogenin sufficient to downregulate PAX7. Indeed, forced expression of either AGER ( Figure 2B and C) (also see, 14) or Myog ( Figure 2F ) results in reduced PAX7 mRNA and protein levels, and inhibition of the proteasome in mock-and Myog-transfected TE671/ WT cells causes PAX7 accumulation ( Figure 2F ). Thus, in ERMSs high expression levels of PAX7, which have been reported to be responsible for absent or low RAGE levels (14) , might be also responsible for low myogenin levels (1,3) which in turn makes these tumors unable to downregulate PAX7. Because PAX3 and PAX7 play a role in the migration of muscle precursor cells from the somatic dermamyotomes to limb buds during embryonic development (27) (28) (29) , a link between PAX genes and the metastatic potential of ERMS cells has been proposed (12), but not formally proven. We show that PAX7 confers a metastatic behavior on cells of muscle lineage, since PAX7 knockdown or overexpression significantly reduces and increases, respectively, cell migration and invasiveness of ERMS cells and primary myoblasts in vitro (Figure 2 and Supplementary Figure 2 , available at Carcinogenesis Online). These effects rely at least in part on the ability of PAX7 to upregulate EPHA3 and EFNA1 and downregulate NCAM1 expression thus resulting in a predominance of PSA-NCAM over NCAM. Reintroduction of RAGE in ERMS cells significantly reduces PAX7 levels with consequent downregulation of EPHA3 and EFNA1 and upregulation of NCAM.
By mediating cell-cell adhesion or repulsion, EPHs and EFNs have been involved in invasiveness in cancer, wherein EPHs and EFNs might have different effects depending on the tumor cell type and the presence of cognate ligands/receptors (21, 30, 31) . Specifically, the expression of EPHA3 is restricted to ERMSs and translocation-negative ARMSs (32) , and EFNA1 promotes tumor growth, angiogenesis and metastasis in patients with α-fetoprotein-producing hepatocellular carcinoma (33) , and supports migration and invasion in HeLa cells (34) . We show here that the co-expression of EPHA3 and EFNA1 sustains migration and invasiveness in ERMS cells in vitro. Combined with the reduced metastatic behavior of TE671/RAGE cells, which express lower levels of EPHA3 and EFNA1 compared with TE671/ WT cells (Supplementary Table 2 , available at Carcinogenesis Online), our results suggest that upregulation of EPHA3 and EFNA1 and PAX7 coincidently with or consequent to absent or low RAGE/ myogenin levels might concur to an aggressive and metastatic phenotype of ERMS cells. Although PAX genes, including PAX7, have been shown to upregulate several EPHs and EFNs in different cell types (12) , to our knowledge this is the first evidence for a role of PAX7 in the upregulation of EPH and EFN members (particularly, EPHA3 and EFNA1) in ERMS cells. The presence of specific binding sites for PAX family members in the promoter regions of human EPHA3 (Gene ID: 2042) and EFNA1 (Gene ID: 1942) genes (23 and 16 putative PAX7 binding sites, respectively) supports a role for PAX7 as a stimulator of EPHA3 and EFNA1 expression.
Loss of NCAM has been involved in the progression of tumor metastases (35) , and polysialylation of NCAM modulates NCAM adhesive functions and is important for the enhanced invasive potential of tumor cells (36) . Polysialylation of NCAM on the surface of TE671 cells plays a major role in primary tumor and metastasis formation, because the enzymatic removal of PSA by endoneuraminidase-N treatment in these cells reduces i.p. tumorigenesis and occurrence of metastases (16) . We found that PAX7 activity in muscle precursor and ERMS cells translates into downregulation of Ncam1/NCAM1 expression. Although several PAX genes have been reported to affect NCAM1 expression, with high concentrations of PAX3 leading to a significant inhibition (37) , a link between PAX7 and NCAM1 gene activity was not reported. The polysialyltransferase gene, ST8SIAII, also is under the control of PAX3 (38) , which links PAX genes activity to NCAM polysialylation. However, we found that neither RAGE nor PAX7 appears to significantly affect ST8SIAII levels in ERMS and muscle precursor cells ( Figure 4B and C) . Moreover, microarray analysis showed no RAGE-dependent stimulation of PAX3 expression in TE671 cells (data not shown). Thus, it is a PAX7-dependent downregulation of NCAM1 that is mainly responsible for the observed increase in PSA-NCAM/NCAM expression ratio that promotes migration and invasiveness in PAX7-overexpressing cells ( Figure 4A-C) . Since NCAM is the closest known homolog of RAGE (25) it is possible that RAGE might additionally affect NCAM molecular interactions at the cell surface by, e.g. preventing its polysialylation. Interestingly, a close structural relationships of RAGE with the cell adhesion proteins, ALCAM, BCAM and MCAM, has been reported, and RAGE expression on the cell surface of several cell types increases cell adhesion to extracellular matrix components, and between cells themselves through homophilic interaction of the RAGE V-domain (39) .
To get more insights into the effects of ectopic expression of RAGE in TE671 cells, we compared gene expression in TE671/RAGE cells with that in TE671/WT cells and that in hu-Ms, i.e. the cell type from which ERMSs are believed to originate (4, 5) . We found that reintroduction of RAGE in TE671 cells results in changes in gene expression profile compatible with the observed behavior of TE671/RAGE versus TE671/WT cells. Indeed, compared with TE671/WT cells, TE671/ RAGE cells show increased expression of genes that sustain myogenic differentiation and genes involved in cell adhesion, and reduced expression of genes related to cell migration (Supplementary Tables  3 and 4 , available at Carcinogenesis Online). In hu-Ms most of these genes show similar changes to TE671/RAGE cells. Interestingly, several genes related to muscle development and differentiation that are upregulated in TE671/RAGE versus TE671/WT cells, are downregulated or unchanged in hu-Ms; this is in accordance with the notion that ERMS cells express markers of muscle differentiation despite their inability to differentiate (2, 4) , and with the pro-differentiative role of RAGE in cells of the myogenic lineage (8) (9) (10) (11) . Notably, myostatin, which inhibits RMS cell proliferation (40) , turned out to be one of the most upregulated genes in TE671/RAGE versus TE671/WT cells (Supplementary Table 3 Table 2 , available at Carcinogenesis Online).
Unexpectedly, we found a dramatic decrease in the expression of MHC class I genes in TE671/RAGE cells compared with TE671/WT cells (Supplementary Table 5 , available at Carcinogenesis Online). Previous work has shown that constitutive expression of MHC class I in C57 myoblasts significantly decreases myogenic differentiation in vitro and in vivo (41) , suggesting that overexpression of genes of the immune response in muscle precursor cells might hamper differentiation, thus potentially concurring to oncogenic conversion. We present first evidence that RAGE signaling in muscle precursor cells might play a role in repressing the expression of MHC class I genes; loss of self-molecules subsequent to the downregulation of MHC class I genes might allow cells to escape detection by cytolytic T cells and make them sensitive to NK cell cytotoxicity by a 'missing self' recognition mechanism (15) . This might concur to the dramatic reduction of tumor formation and metastasis observed following injection of TE671/RAGE cells into irradiated nude mice, also in consideration that NK activity in these animals is not entirely abrogated by γ irradiation (42) .
Taken together, our results suggest that downregulation of PAX7 through RAGE-induced myogenin in ERMS cells might serve a dual function, i.e. promoting terminal differentiation and reducing proliferation, and repressing the expression of molecules responsible for cell migration and invasiveness ( Figure 6 ). In line with the notion that multiple events have to cooperate for tumor development (43, 44) , loss of RAGE expression in muscle precursor cells (i.e. Ager -/-myoblasts) is not sufficient to lead to oncogenic conversion per se. However, we previously reported that functional inactivation of RAGE in the myoblast cell line, L6, results in tumor formation in vivo (10) . Thus, it can be hypothesized that a stochastic loss of RAGE expression and/ or functionality in muscle precursor cells during specific phases of muscle development or repair might lead to rhabdomyosarcomagenesis provided additional predisposing events also occur. Interestingly, RAGE is absent or expressed at very low levels in a panel of 31 human ERMSs (14) . By this point of view, the primary tumors and metastases observed in mice injected with TE671/RAGE cells might derive from selected clones that have lost the ability to express sufficient RAGE on their cell surface. Supporting this, we found that the lung metastases of mice injected with TE671/RAGE cells express very low levels of RAGE compared with their primary tumors (Supplementary Figure 3B , available at Carcinogenesis Online), suggesting that PAX7 sustains ERMS invasiveness individual (low-RAGE expressing) clones acquire the ability to migrate and invade distant organs.
RAGE is generally considered as a factor promoting proliferation, survival, migration, and invasion of tumor cells, as are the cases with glioma, melanoma and pancreas, prostate and colon cancers (45) . Nevertheless, RAGE expression in nonsmall cell lung carcinoma and oral and esophageal squamous cell carcinomas negatively correlates with tumor growth and depth of invasion (46) (47) (48) , similar to ERMS cells. The reason why RAGE has opposite roles depending on the tumor cell type should be further investigated, and this ambiguous behavior suggests that caution should be exerted in setting RAGEtargeted anticancer protocols.
Whereas the molecular mechanisms responsible for the inability of ERMSs to exit the cell cycle and differentiate are not fully elucidated, elevated levels of PAX7 play a role in impeding cell proliferation arrest and myogenic differentiation by reducing the levels of the myoblast proliferation inhibitor, MyoD, and the essential myogenic factor, myogenin (14, 18) , and promoting invasiveness and metastasis formation (present work) in ERMS cells. Forced expression of RAGE in these cells, besides reducing proliferation and inducing differentiation (11, 14) , translates into a significant reduction of tumorigenesis and metastatic potential mainly through myogenin-dependent downregulation of PAX7 expression. Notably, forced expression of myogenin in the poorly differentiated human ERMS-derived RD/12 cell line resulted in the acquisition of a more differentiated phenotype, and reduction of tumor growth and liver metastasis (49) . Thus, overexpression of RAGE appears negatively linked to ERMS invasive properties. Further investigation should establish the clinical correlation between RAGE expression in ERMS primary tumors and their outcome in patients, particularly with regard to metastasis occurrence.
Supplementary material
Supplementary Tables 1-5 and Figures 1-3 6 . Schematics of the proposed pathway controlling PAX7 expression levels, and the role of PAX7 in ERMS cell migration and invasiveness. Ectopic expression of RAGE in ERMS cells results in the activation of a RAGE/p38 MAPK/myogenin axis that promotes differentiation and inhibits proliferation through inhibition of JNK and ERK1/2 kinases (11), and upregulation of the myoblast proliferation inhibitor, MyoD (14) . At the same time, RAGE engagement in ERMS cells translates into myogenin-dependent downregulation of PAX7 expression at a transcriptional and post-translational level, as in normal myoblasts (9, 14, 21) . Reduced PAX7 levels allow terminal differentiation (21, 24) , and result in the upregulation of NCAM1 and downregulation of EPHA3 and EFNA1, which translates into a less invasive cell behavior.
